SCHEMBL3284681

SCHEMBL3284681

CCOC(=O)C(C)(C)Sc1cccc(CCCCNc2nn(CCCC(F)(F)F)c(=O)n(Cc3ccccc3)c2=O)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.36
MEN1 O00255 4/20 0.36
TP53 P04637 3/20 0.34
MAPT P10636 3/20 0.34
LMNA P02545 2/20 0.33
PPARA Q07869 4/20 0.32
PPARG P37231 2/20 0.32
PPARD Q03181 1/20 0.32
POLB P06746 1/20 0.32
AGTR2 P50052 1/20 0.32
TPSAB1 Q15661 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
IDE P14735 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3284391 0.92 PPARA (0.38) TP53PPARAPPARGKDM4EALDH1A1
SCHEMBL3284363 0.91 PPARA (0.40) KMT2AMEN1TP53MAPTPPARA
SCHEMBL3285912 0.91 PPARA (0.34) KMT2AMAPTLMNAPPARAPPARG
SCHEMBL3844552 0.91 SLC22A12 (0.34) TP53MAPTLMNAPPARAPPARG
SCHEMBL3284562 0.89 PPARA (0.34) MAPTPPARAPPARGKDM4EALDH1A1
SCHEMBL3284140 0.86 PPARA (0.49) KMT2AMEN1PPARAPPARGPPARD
SCHEMBL3285942 0.86 PPARA (0.42) KMT2AMEN1TP53MAPTPPARA
SCHEMBL3286592 0.86 PPARA (0.41) TP53PPARAPPARGPPARDKDM4E
SCHEMBL3285907 0.84 PPARA (0.47) KMT2AMEN1PPARAPPARGPPARD
SCHEMBL3844324 0.84 PPARG (0.38) TP53PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713971-B2 1,2,4-triazine derivatives, preparation and use thereof in human therapy PIERRE FABRE MEDICAMENT (FR) 2010-05-11 US claimed
EP-1856065-B1 1,2,4-TRIAZINE DERIVATIVES, PREPARATION AND USE THEREOF IN HUMAN THERAPY PF MEDICAMENT (FR) 2009-11-11 EP claimed
US-20080167313-A1 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy PIERRE FABRE MEDICAMENT (FR) 2008-07-10 US claimed
US-7713971-B2 1,2,4-triazine derivatives, preparation and use thereof in human therapy PIERRE FABRE MEDICAMENT (FR) 2010-05-11 US disclosed
US-7713971-B2 1,2,4-triazine derivatives, preparation and use thereof in human therapy PIERRE FABRE MEDICAMENT (FR) 2010-05-11 US disclosed
US-7713971-B2 1,2,4-triazine derivatives, preparation and use thereof in human therapy PIERRE FABRE MEDICAMENT (FR) 2010-05-11 US disclosed
US-20080167313-A1 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy PIERRE FABRE MEDICAMENT (FR) 2008-07-10 US disclosed
US-20080167313-A1 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy PIERRE FABRE MEDICAMENT (FR) 2008-07-10 US disclosed
US-20080167313-A1 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy PIERRE FABRE MEDICAMENT (FR) 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167313-A1 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy CBR3, NOX3, RTN3 KMT2A 4443/4885MEN1 2831/4885TP53 3764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.